Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that chloroquine will reduce the ability
of ductal carcinoma in situ (DCIS) to survive and spread. Participants will receive either
chloroquine standard dose (500mg/week) or chloroquine low dose (250mg/week) for 1 month prior
to surgical removal of the tumor.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Inova Health Care Services
Collaborators:
George Mason University U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command United States Department of Defense University of Pittsburgh University of Pittsburgh Medical Center